References
- Jemal A, Murray T, Ward E et al. Cancer Statistics, 2005. CA Cancer J. Clin.55, 10–30 (2005).
- Boige V, Malka D, Ducreux M. Therapeutic strategies using VEGF inhibitors in colorectal cancer. Bull. Cancer92, S29–S36 (2005).
- Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat. Rev. Cancer6, 753–763 (2006).
- Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J. Clin.56, 69–83 (2006).
- Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2007. CA Cancer J. Clin.57, 43–66 (2007).
- Heart Protection Study Collaborative; Mihaylova B, Briggs A, Armitage J et al. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. Br. Med. J.333, 1145 (2006).
- Pignone M, Earnshaw S, Tice JA et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost–utility analysis. Ann. Intern. Med.144, 326–336 (2006).
- Gaspardone A, Versaci F. Coronary stenting and inflammation. Am. J. Cardiol.96, 65L–70L (2005).
- Mulcahy HE, O’Donoghue DP. Duration of colorectal cancerCEA symptoms and survival: the effect of confounding clinical and pathological variables. Eur. J. Cancer33, 1461–1467 (1997).
- Kelloff GJ, Lippman SM, Dannenberg AJ et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer – a plan to move forward. Clin. Cancer Res.12, 3661–3697 (2006).
Website
- American Cancer Society: Cancer Statistics 2006 Presentation www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Statistics_2006 _Presentation.asp